Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective one arm study to explore the efficacy and safety of Hetrombopag in
non-severe aplastic anemia. Patients meeting the inclusion and exclusion criteria would be
recruited. Treatment of Hetrombopag would be started with 5mg/day. The dosage would be
increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and
reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.
All patients would receive treatment for at least 6 months except that the platelet
<20×10e9/L at the dosage of 15mg/day for 4 weeks or the platelet ≥200×10e9/L at the dosage of
5mg/week for 2 weeks. The hematological response rate and safety will be recorded and
compared at D15, 1month, 1.5month, 2month, 3month, 4month, 5month, 6month, 8month, 10month
and 1year.